To determine comparative 1-year outcomes in renally impaired patients who previously
underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial
protocol and were evaluable for determination of post-contrast significant renal injury
(defined as >25% increase in SCr or >25% increase in cystatin C).